Fresh analysis indicates that people who stop using new slimming jabs like semaglutide or tirzepatide can put back on reduced body mass far faster than those who halt conventional lifestyle regimens.
Findings released in a major health publication shows that while obese individuals often shed substantial amounts of their body weight while undergoing treatment, the mass returns at an average rate of 0.8 kg per month after stopping.
"People buying such drugs must be aware of the potential of rapid weight regain when the treatment ends," cautioned lead investigator Dr. Susan Jebb.
This pace of recovery implies a reversion to starting mass within about 18 months.
Comparing Therapies
The study, which looked at dozens of trials involving over 9,000 of participants, compared the results of GLP-1 agonists with older methods.
The team emphasize that people who shed pounds through dieting generally have a slower weight regain—perhaps 0.1 kg a month—after stopping.
Explaining the Rapid Regain
Experts propose the way of the injections is key to understanding the heightened weight return.
The injections copy a natural hormone called glucagon-like peptide-1, which controls appetite.
"Artificially providing the hormone concentrations several times higher than normal might result in the body to generate a reduced amount of its endogenous GLP-1, and could reduce responsiveness to its effects," explained Dr. Adam Collins, a dietetics expert.
"Discontinuation of this GLP-1 'fix' results in appetite is unsuppressed, making excessive eating a significant risk."
A Lifelong Issue?
The NHS advise the jabs for individuals with weight-linked medical conditions, accompanied by prescribed lifestyle changes.
Many experts argue that, due to the likelihood of weight regain, the treatment might need to be ongoing.
This opinion is reinforced by drug manufacturers, who say that the results "emphasize the chronic nature of excess weight," comparing it to managing conditions like hypertension.
User Testimonies
Individuals who have stopped the medication describe a powerful resurgence of cravings.
"It was like something activating and you become starving," recalled one woman.
The struggle is worsened if individuals have not adopted permanent dietary or behavioural modifications during treatment.
Growing Interest
Survey data show that a significant number of people in the UK have tried weight-loss jabs in the past year, with interest continuing to grow.
- Adoption is more common among females than males.
- The 40s and 50s age group shows the greatest level of interest.
- Many obtain the drugs through private healthcare rather than public health services.
Ultimately, experts stress that while GLP-1 drugs are potent tools for weight loss, they are not a standalone cure and long-term success relies on integrated lifestyle support.
